杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/06/20 | 1,757 | 1,764 | 1,748 | 1,764 | ±0 | ±0% | 45,400 |
2023/06/19 | 1,759 | 1,771 | 1,752 | 1,764 | +7 | +0.4% | 57,400 |
2023/06/16 | 1,738 | 1,759 | 1,737 | 1,757 | +16 | +0.9% | 202,700 |
2023/06/15 | 1,734 | 1,748 | 1,733 | 1,741 | +3 | +0.2% | 83,200 |
2023/06/14 | 1,748 | 1,748 | 1,733 | 1,738 | -8 | -0.5% | 81,900 |
2023/06/13 | 1,750 | 1,759 | 1,741 | 1,746 | ±0 | ±0% | 99,200 |
2023/06/12 | 1,748 | 1,753 | 1,735 | 1,746 | +7 | +0.4% | 86,600 |
2023/06/09 | 1,751 | 1,751 | 1,733 | 1,739 | +2 | +0.1% | 139,300 |
2023/06/08 | 1,735 | 1,744 | 1,725 | 1,737 | +10 | +0.6% | 97,300 |
2023/06/07 | 1,741 | 1,753 | 1,723 | 1,727 | -19 | -1.1% | 113,500 |
2023/06/06 | 1,733 | 1,746 | 1,717 | 1,746 | +9 | +0.5% | 115,400 |
2023/06/05 | 1,733 | 1,758 | 1,725 | 1,737 | -36 | -2% | 207,600 |
2023/06/02 | 1,749 | 1,773 | 1,747 | 1,773 | +30 | +1.7% | 91,800 |
2023/06/01 | 1,750 | 1,762 | 1,740 | 1,743 | +12 | +0.7% | 104,000 |
2023/05/31 | 1,751 | 1,760 | 1,718 | 1,731 | -33 | -1.9% | 376,300 |
2023/05/30 | 1,782 | 1,782 | 1,756 | 1,764 | -22 | -1.2% | 60,700 |
2023/05/29 | 1,780 | 1,799 | 1,769 | 1,786 | +27 | +1.5% | 82,300 |
2023/05/26 | 1,793 | 1,793 | 1,758 | 1,759 | -36 | -2% | 72,100 |
2023/05/25 | 1,786 | 1,808 | 1,781 | 1,795 | +9 | +0.5% | 127,300 |
2023/05/24 | 1,795 | 1,796 | 1,782 | 1,786 | -4 | -0.2% | 104,100 |
2023/05/23 | 1,784 | 1,794 | 1,779 | 1,790 | +14 | +0.8% | 177,900 |
2023/05/22 | 1,747 | 1,778 | 1,746 | 1,776 | +35 | +2% | 66,800 |
2023/05/19 | 1,755 | 1,755 | 1,735 | 1,741 | -4 | -0.2% | 66,300 |
2023/05/18 | 1,770 | 1,770 | 1,742 | 1,745 | -17 | -1% | 64,300 |
2023/05/17 | 1,763 | 1,769 | 1,756 | 1,762 | -4 | -0.2% | 57,800 |
2023/05/16 | 1,750 | 1,766 | 1,745 | 1,766 | +22 | +1.3% | 89,400 |
2023/05/15 | 1,740 | 1,749 | 1,737 | 1,744 | +11 | +0.6% | 64,100 |
2023/05/12 | 1,730 | 1,740 | 1,723 | 1,733 | +13 | +0.8% | 88,100 |
2023/05/11 | 1,732 | 1,733 | 1,718 | 1,720 | -22 | -1.3% | 46,300 |
2023/05/10 | 1,753 | 1,753 | 1,739 | 1,742 | -14 | -0.8% | 56,000 |
2023/05/09 | 1,759 | 1,759 | 1,752 | 1,756 | +7 | +0.4% | 50,800 |
2023/05/08 | 1,741 | 1,761 | 1,741 | 1,749 | +10 | +0.6% | 58,500 |
2023/05/02 | 1,760 | 1,763 | 1,733 | 1,739 | -16 | -0.9% | 65,600 |
2023/05/01 | 1,755 | 1,761 | 1,748 | 1,755 | +8 | +0.5% | 64,000 |
2023/04/28 | 1,748 | 1,752 | 1,740 | 1,747 | +21 | +1.2% | 77,400 |
2023/04/27 | 1,724 | 1,732 | 1,718 | 1,726 | +2 | +0.1% | 56,800 |
2023/04/26 | 1,738 | 1,738 | 1,720 | 1,724 | -17 | -1% | 46,500 |
2023/04/25 | 1,733 | 1,748 | 1,733 | 1,741 | +15 | +0.9% | 94,000 |
2023/04/24 | 1,723 | 1,735 | 1,718 | 1,726 | +3 | +0.2% | 110,600 |
2023/04/21 | 1,729 | 1,733 | 1,722 | 1,723 | -8 | -0.5% | 53,100 |
2023/04/20 | 1,722 | 1,735 | 1,722 | 1,731 | +2 | +0.1% | 57,400 |
2023/04/19 | 1,735 | 1,735 | 1,724 | 1,729 | -11 | -0.6% | 43,400 |
2023/04/18 | 1,729 | 1,742 | 1,729 | 1,740 | +18 | +1% | 52,300 |
2023/04/17 | 1,735 | 1,735 | 1,716 | 1,722 | -12 | -0.7% | 37,600 |
2023/04/14 | 1,726 | 1,735 | 1,723 | 1,734 | +20 | +1.2% | 84,700 |
2023/04/13 | 1,709 | 1,717 | 1,705 | 1,714 | +8 | +0.5% | 46,600 |
2023/04/12 | 1,722 | 1,726 | 1,705 | 1,706 | -11 | -0.6% | 45,000 |
2023/04/11 | 1,719 | 1,722 | 1,704 | 1,717 | +6 | +0.4% | 89,200 |
2023/04/10 | 1,715 | 1,718 | 1,702 | 1,711 | +3 | +0.2% | 32,600 |
2023/04/07 | 1,696 | 1,715 | 1,696 | 1,708 | +9 | +0.5% | 57,000 |
351~
400
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 148,800円 | +3.2% | +4.5% | 3.49% | 17.10倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 223,200円 | +13.6% | +29.2% | 2.06% | 11.58倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,400円 | +197.7% | - | 0.00% | 46.35倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 71,400円 | -3.7% | -36.7% | 2.80% | 23.51倍 | 1.54倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム